An Untested Remedy for an Endangered Tribe: Medical and Administrative Ethics
PYQ Deep Decode
Read the question the way the examiner set it: the demand, the hidden demand, the structure that follows from both, and how the answer should be presented, opened and closed.
1.1 The demand
A short case with a direct question (“Should the DM use this research?”) and two named lenses: medical ethics and administrative ethics. The answer must reach a verdict, and justify it through each lens in turn. The facts that decide it are in the question: an endangered tribe, a severe condition, a possible remedy, and no clinical trials yet.
| Words in the question | What they ask you to do | What goes wrong if you miss them |
|---|---|---|
| An endangered tribe | See a small and potentially vulnerable community whose collective welfare needs special safeguards; do not assume it is a Particularly Vulnerable Tribal Group. | Treating the tribe as any population. |
| severe skeletal deformity | Recognise real suffering and a duty to act: doing nothing is also a choice. | An answer that only says no, with no care for the suffering. |
| a possible remedy, though clinical trials are yet to be conducted | Name the core problem: safety and effectiveness for this use have not been established through clinical trials. | Calling it a “cure” because a university found it. |
| Should the District Magistrate (DM) use this research on the tribe? | Give a clear verdict: not as a remedy now; and say what the DM should do instead. | Sitting on the fence. |
| Discuss from the perspective of medical and administrative ethics | Apply both lenses: medical (beneficence, non-maleficence, autonomy, justice) and administrative (authority, duty of care, accountability). | Only one lens, or a blended list. |
1.2 The hidden demand
The hard question beneath the case is whether urgency of suffering can justify an unproven intervention on people with limited power to refuse. A district administration carries authority in a tribal hamlet; a “yes” from people who depend on it may not be free. The Tuskegee syphilis study (1932-1972), in which participants were denied informed consent and available treatment, shows the danger of exploiting vulnerable populations and underlines the need for independent ethical review, genuine consent and protection against research-related harm. A strong answer faces this in a short part and offers the ethical alternative: help now through proven care, and test the supplement through an approved trial with real consent.
Each point should name the principle, apply it to the facts, and say what it requires the DM to do. The last column is where the hidden demand begins.
| Principle | Applied to the case | What it requires |
|---|---|---|
| Non-maleficence | Clinical trials for the proposed use have not been conducted; its effective dose, safety and possible interactions in this population remain unestablished. | Do not administer it as a remedy until tested. |
| Autonomy | Dependence on public services may create undue influence. | Free, informed consent from each participant, with community engagement and assurance that refusal costs nothing. |
1.3 The structure
The question names two lenses and carries one hidden demand. So a useful answer has three parts, ending in the ethical alternative. The shares are of the body between the introduction and the conclusion; they are a teaching guide, not a UPSC rule.
| Beneficence | The wish to relieve suffering is right; but benefit is unproven. |
| Non-maleficence | Safety, effective dosage and adverse effects for the proposed use have not been established through clinical trials; an unjustified intervention could cause serious harm to a vulnerable population. |
| Autonomy | Free, informed consent from each participant in an understandable language, supported by culturally appropriate community consultation. Permission from community leaders or gatekeepers must not replace individual consent. |
| Justice | A vulnerable group must not bear experimental risk that others would not. |
| Limits of authority | The DM is not a clinical-trial licensing or ethics-review authority. Trials require Ethics Committee approval and applicable regulatory clearance. Qualifying academic trials under Rule 28 of the New Drugs and Clinical Trials Rules, 2019, are exempt from separate Central Licensing Authority permission. |
| Duty of care | Must act: diagnosis, proven treatment, nutrition, specialists. |
| Accountability | The State answers for any harm it causes; the Rule of Law protects the weakest most. |
| Ethical alternative | Facilitate independent scientific assessment and, if justified, ethically reviewed research with consent and monitoring. |
Urgency justifies speed in proper testing and in proven care, not bypassing the safeguards that protect people with little power to refuse.
1.4 How to present it
The form follows the question. Two named lenses call for two headings with principles as points. Because the verdict leads to a path (from untested idea to approved trial), a short flow diagram inside the answer shows what the DM should do instead.
| Form | Fit here | Reason |
|---|---|---|
| Headed points plus a path diagram | Best | Lenses as points; the alternative as a sequence. |
| Two-column table | Good | Medical and administrative side by side. |
| Options with merits and demerits | Possible | Fits a 20-mark case better than a 10-mark question. |
1.5 The introduction and the conclusion
Keep this decode with you. Download the complete decode of this question as a free, print-ready PDF. A one-time sign-up opens every free download on the site.
Download the free PDFPYQ Intelligence: Selected Questions, 2021 to 2026
The question’s context in 2026, its place in a line of questions on medical ethics, consent and the duties of a district officer, and what to prepare next.
2.1 Why the subject was topical in 2026
The 2026 GS IV paper tested consent and medical ethics in three questions. UPSC never states why it sets a question, so treat this as context, not cause.
| When | What happened | Why it matters for this question |
|---|---|---|
| October 2024 | The World Medical Association adopts a revised Declaration of Helsinki, its ethical principles for medical research involving human participants. | The international standard for research on people. |
| November 2023 | PM-JANMAN launched for Particularly Vulnerable Tribal Groups, including health services. | The State’s duty of care to the most vulnerable tribes. |
| 2026 | The same paper tests paternalism and beneficence (Q4(a)) and the limits of surgical consent (Q7); related administrative questions include Q1(b), Q5(a) and Q6(a). | Consent and beneficence as a theme of the year. |
2.2 The skill UPSC keeps testing
These questions share one concern: doing good to people without overriding their choice or exposing them to harm.
| Year | The question as UPSC set it, or a marked summary | What it asked of you | What changed in 2026 |
|---|---|---|---|
| 2021 GS IV | Summary, not verbatim: Q10, a public hospital administrator must justify exposing staff to infectious patients during COVID-19 amid shortages. | Risk, duty and scarcity in health care. | Non-maleficence and administrative duty again. |
| 2023 GS IV | In the context of work environment, differentiate between “coercion” and “undue influence” with suitable examples. (Q2(b)) | Coercion and undue influence. | Why consent from a dependent community may not be free. |
| 2023 GS IV | Summary, not verbatim: Q8, after a landslide near Uttarkashi, a District Magistrate with medical training faces an emergency blood-transfusion dilemma without recognised blood-bank arrangements. | Medical urgency against procedural safeguards. | The closest precedent: a DM, medicine and rules. Urgency with a proven procedure differs from a speculative remedy. |
| 2024 GS IV | Summary, not verbatim: Q12, a scientist pressed to speed up a drug trial as colleagues propose data manipulation and bypassing informed consent. | Integrity and consent in research. | From research misconduct to an administrator tempted to skip research altogether. |
| 2026 GS IV | Citing the serious adverse effects of long-term medication, a doctor convinces the family of a female patient for surgery. This led the patient to reluctantly consent for the surgery, though her original choice was to opt for medication. Explain the concepts of paternalism and beneficence by analysing the doctor’s action. (Q4(a)) | Paternalism against autonomy. | The same tension, now with the State as the well-meaning actor. |
| 2026 GS IV | Summary, not verbatim: Q7, a patient’s consent for one procedure and a surgeon’s decision during surgery. | Scope and limits of consent. | Consent again, for a community rather than one patient. |
- Give the verdict first.
- Apply each lens named.
- Name the principle in each point.
- Offer the ethical alternative.
- Test the excuse of urgency.
2.3 What to prepare next
Medical ethics
| Four principles | Autonomy, beneficence, non-maleficence, justice. |
| Informed consent | Information, understanding, voluntariness. |
| Paternalism | Overriding choice for a person’s own good. |
| Research ethics | Nuremberg, Helsinki, Belmont, ICMR 2017. |
Tribal welfare and health
| PVTGs | 75 groups; PM-JANMAN (2023). |
| Sickle cell mission | National Sickle Cell Anaemia Elimination Mission (2023), largely in tribal areas. |
| Article 21 and 47 | Article 21: right to life, read to include timely medical care (Paschim Banga Khet Mazdoor Samity, 1996). Article 47: nutrition and public health. |
| Community engagement | Consultation with community elders, culturally appropriate representatives and relevant local bodies, including the Gram Sabha where applicable; individual informed consent remains essential for participation in research. |
Additional information
Everything needed to answer this question well. Tier 1 holds what the demand needs; Tier 2 places it within the wider debate on research, consent and the State’s duty to vulnerable communities.
What the DM should do instead: the ethical path
| Subject | What it is | Why it matters for the answer |
|---|---|---|
| Medical ethics | ||
| Four principles | The ICMR National Ethical Guidelines (2017) rest on respect for persons (autonomy), beneficence, non-maleficence and justice. | The vocabulary of Part 1. |
| Informed consent | ICMR 2017: comprehensible information, adequate understanding and voluntary participation, in the participant’s language; an impartial witness where specified for participants who cannot read; audio-visual recording for prescribed categories of trials. | Why a request from the administration is not consent. |
| Vulnerability | ICMR 2017 treats people disadvantaged by economic or social status or hierarchical relationships as vulnerable; they need added safeguards and should be included when research addresses their needs. | The tribe is vulnerable on several counts. |
| Community engagement | ICMR 2017 asks for engagement “before, during and after” research; community agreement does not replace individual consent. Section 6.7 (research among tribal populations) adds entry approval from a competent administrative authority, such as the District Collector, consultation with elders and consent in the local dialect. | Community engagement must accompany individual consent; gatekeeper permission never replaces it. |
| The rules | ||
| Clinical trials | Under the New Drugs and Clinical Trials Rules, 2019, clinical trials of new or investigational drugs generally need Central Licensing Authority permission and approval from a registered Ethics Committee. Rule 28 lets a qualifying academic trial of an already permitted drug for a new indication, route, dose or dosage form proceed without separate permission, provided prior Ethics Committee approval and the other conditions are met; its results cannot be used for promotion or marketing approval. | Why a DM cannot authorise a trial. |
| Supplement or drug? | Classification depends on formulation, dose, intended use and claims. FSSAI-regulated health supplements may not claim to prevent, treat or cure disease; a proposed medicinal use may attract drug regulation and research permissions. | Closes the loophole a weak answer might use. |
| International codes | Nuremberg Code (1947): voluntary consent essential; Declaration of Helsinki (1964, latest revision 2024); Belmont Report (1979): respect for persons, beneficence, justice. | The standards behind the Indian rules. |
| Administrative ethics | ||
| Authority | A DM coordinates services and cannot authorise a regulated trial by executive order. ICMR 6.7.2 does, however, call for approval from a competent administrative authority, such as the District Collector, before researchers enter tribal areas; this is separate from ethics review and drug-regulatory permission. | Acting beyond authority is itself an ethical failure. |
| Duty of care | Article 21 supports the State’s obligation to provide timely medical care; Article 47 directs improvement of nutrition and public health. The DM must mobilise health services. PVTG programmes such as PM-JANMAN apply only if the community is a recognised PVTG. | Inaction is not an option. |
| Accountability | The DM must document decisions, ensure lawful oversight and secure access to treatment and redress; research-injury compensation follows the applicable rules. | Why procedure is a form of care, not red tape. |
Thinkers and ideas that fit
| Kant | Persons are ends, never merely means: a tribe cannot be a test site for others’ knowledge. |
| Mill’s harm principle | In On Liberty (1859), Mill generally rejects coercing competent adults merely for their own good; preventing harm to others is the principal justification for interference. |
| Precautionary principle | Where harm may be serious or irreversible, lack of certainty is a reason for caution. |
| Gandhi’s talisman | Will the step help the poorest and weakest, as they themselves see it? |
Arguments for acting fast
- Suffering: severe deformity now.
- Survival: an endangered tribe at risk.
- Low risk claim: minerals may seem harmless.
- Access: trials may never reach remote groups.
Why caution prevails
- Unknown harm: even minerals are toxic in excess.
- Small population: harm could be irreversible for the group.
- Consent: power imbalance with the administration.
- Trust: one failure can close a community to all health services.
- History: research abuses on marginalised groups.
Two debates worth knowing
The Declaration of Helsinki (2024, paragraph 37) addresses exceptional use of an unproven intervention for an individual patient when approved options are inadequate or ineffective and enrolment in a trial is impossible. The physician must seek expert advice, weigh risks and benefits, obtain informed consent, record and share data, and support later safety and efficacy research. It grants no regulatory permission and cannot justify population-wide administration. The balanced reading: novel community-wide use needs a sound evidence base and appropriate review.
Too much caution can keep vulnerable groups out of research that could help them. ICMR 2017 says they have a right to benefit from research. The balanced reading: include them through well-designed, consented trials, not by skipping trials.
Pitfalls and variations
The mistakes that cost marks here, the claims never to make, and how the answer changes when the question changes.
4.1 Six pitfalls, each with its correction
4.2 Never write these
- “The DM can approve a clinical trial in his district.” Trials need ethics review and applicable regulatory clearance; under ICMR Guideline 6.7.2, a competent administrative authority such as the Tribal Welfare Commissioner or District Collector approves researchers’ entry into tribal areas, which is separate from ethics and regulatory approval; the DM also coordinates care and protects participants.
- “Tribal people cannot understand consent.” A stereotype; consent must be made understandable, not skipped.
- “Since the tribe is endangered, any risk is worth taking.” Smaller populations make harm more serious.
- “University research is enough evidence.” Without clinical trials for the proposed use, safety and efficacy in the target population remain unestablished; existing toxicological or human data may still be available.
- “The DM should leave it entirely to doctors.” He has a duty to act and coordinate care.
4.3 If the question changes
| If it asks | The structure becomes | What must change |
|---|---|---|
| As a 20-mark case study | Stakeholders; ethical issues; options with merits and demerits; course chosen | Options: administer, refuse, facilitate trial plus care. |
| Ethics of clinical trials in India | Principles, rules, past controversies, safeguards | Regulation becomes central. |
| Paternalism versus autonomy in public health | Concepts, examples, where paternalism is justified | Vaccination, quarantine and consent debates. |
| Duty of the State to PVTGs | Constitutional basis, schemes, ethical approach | Health becomes one dimension among several. |
The model answer
One answer, written in 150 words, in the form this question calls for: points under the two named lenses and a short path diagram for the ethical alternative. The introduction covers the whole question; the conclusion settles its demand.
The DM should not administer an untested supplement to a vulnerable tribe; the suffering demands action, but through proven care and an approved trial.
1. Medical ethics
- Beneficence: intent to relieve suffering is right, but benefit is unproven.
- Non-maleficence: unverified safety and efficacy could expose participants to avoidable harm.
- Autonomy: voluntary individual consent in their language, with community consultation.
- Justice: vulnerable people must not bear experimental risk others avoid.
2. Administrative ethics
- Authority: research requires ethics review and applicable regulatory clearance, not unilateral DM authorisation.
- Duty of care: mobilise specialists to diagnose and treat now.
- Accountability: document decisions, monitor risks and ensure appropriate redress.
3. Does urgency justify it?
Urgency justifies faster testing, not bypassing safeguards for those with little power to refuse.
Both lenses agree: compassion requires evidence and consent; the DM must ensure immediate care without exposing the tribe to unauthorised experimentation.
Other ways to write it
The model answer above remains the answer. These outlines show how a different, equally valid answer could be built, and when each choice works.
| Approach | How it is built | When it works |
|---|---|---|
| Two-column table | Rows for each principle; columns for medical and administrative ethics. | When you want the two lenses compared. |
| Open with a precedent | Introduction recalls that research on marginalised groups without consent has caused lasting harm; then the verdict. | When you want to stress the hidden demand. |
| Options format | Administer now; refuse and wait; care now plus approved trial; choose the third. | When the question asks what the DM should do. |
| For 15 or 20 marks | Add stakeholders and thinkers (Kant, Mill, precaution). | When there is room. |
Quick recall and Prelims crossover
Facts for rapid revision and Prelims.
| 1 | Four principles: autonomy, beneficence, non-maleficence, justice. | 9 | PVTGs: 75 groups (the question does not say the tribe is one). |
| 2 | ICMR National Ethical Guidelines: 2017; twelve general principles. | 10 | PM-JANMAN: launched November 2023. |
| 3 | ICMR 2017 has a section on research among tribal population. | 11 | National Sickle Cell Anaemia Elimination Mission: July 2023. |
| 4 | Consent: information, understanding, voluntariness. | 12 | Article 47: duty to raise nutrition and improve public health. |
| 5 | New Drugs and Clinical Trials Rules: 2019; Rule 28 on academic trials. | 13 | Article 21: right to health read into right to life. |
| 6 | Nuremberg Code: 1947. | 14 | Paternalism: overriding choice for one’s own good (2026 Q4(a)). |
| 7 | Declaration of Helsinki: 1964; revised 2024. | 15 | Precautionary principle: caution where harm may be irreversible. |
| 8 | Belmont Report: 1979. | 16 | Mill’s harm principle: On Liberty, 1859. |
Write it yourself
Write the answer in 150 words without looking back, then check it against each line below.
| Check | Yes / No | |
|---|---|---|
| 1 | Does the introduction give a clear verdict with its reason? | |
| 2 | Are medical and administrative ethics under separate headings? | |
| 3 | Are the four principles applied to the facts? | |
| 4 | Does the answer give the DM’s ethical alternative, not just a refusal? | |
| 5 | Does Part 3 test whether urgency justifies it? | |
| 6 | Does the conclusion state what both lenses agree on, at about the length of the introduction? | |
| 7 | Is it 150 words or a little over, with no claim from section 4.2? |
Write your first answer. Get written feedback, free.
Reading a decode helps you understand the question. Writing your own answer helps you put that understanding into practice. Write this answer and send it to us: your first answer receives a free written evaluation by the UPSC Gurus method.
- Write the answer by hand on A4 sheets, within about 150 words, before you look at the model answer.
- Go through the self-check in section 8 above, then photograph every page clearly (or scan it as one PDF).
- Upload it below. Your written feedback comes to your email: how your answer met the question’s demand and implied dimensions, its structure, content and presentation, and what to work on next.
Explore personalised support
Write any actual UPSC Mains GS paper from 2017 to 2026. Receive written evaluation of every answer by email, followed by a personal feedback session.
Get my paper evaluatedUnderstand where your preparation stands through a structured diagnosis, a written roadmap and one follow-up session. The full counselling fee is adjusted against any UPSC Gurus programme you join within 30 days. This is a fee adjustment, not a refund.
Book counsellingSources
- Indian Council of Medical Research, National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017), including sections 1, 2.2, 2.9, 2.10 and 6.7.
- Central Drugs Standard Control Organisation (CDSCO), New Drugs and Clinical Trials Rules, 2019, particularly Rules 19, 22, 25 and 28 (clinical-trial permission, conditions and academic trials); FSSAI, Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2016, as amended; Paschim Banga Khet Mazdoor Samity v. State of West Bengal, (1996) 4 SCC 37 (timely medical treatment).
- Nuremberg Code (1947); World Medical Association, Declaration of Helsinki (1964, revised 2024); The Belmont Report (1979).
- Ministry of Tribal Affairs, PM-JANMAN (2023); National Sickle Cell Anaemia Elimination Mission (2023).
- UPSC Civil Services (Main): GS Paper IV 2021, 2023, 2024 and 2026 (Q2(a), Q4(a), Q7). Official question papers.
Your first Mentor’s Desk call is free
One free conversation per aspirant about where you are in your preparation, with an honest suggestion of the right next step.
Know more and bookHave a question? Get in touch
For questions about a programme, its fees, batch dates, payment or access. Message us on WhatsApp and our team will reply. Asking a question is not a booking, and you can ask as often as you need.
Get in touch on WhatsApp
